ASX · MYX.AX
Mayne Pharma Group Limited
A$2.54+A$0.04 (+1.6%)
Mayne Pharma Group Limited’s quoted price sits in the lower half of its reported 52-week range, 57.95% below the high.
Loading market information…
ASX · VLS.AX · AUD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 05:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Vita Life Sciences Limited’s quoted price sits in the upper half of its reported 52-week range, 5.52% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Vita Life Sciences Limited’s forward annual dividend is A$0.10 per share, paid semi-annual. The forward yield is 3.65% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vita Life Sciences Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vita Life Sciences Limited is an Australian healthcare company specializing in the formulation, packaging, distribution, and sale of vitamins and nutritional supplements. The company's reach spans Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. In addition to core supplements, their product range encompasses minerals, various herbs, and superfoods. They offer solutions targeting a broad spectrum of therapeutic areas, including nervous system support, general nutrition, immunity, hair, skin, and nails, liver and digestion, weight management, cardiovascular health, pain and inflammation, pregnancy and breastfeeding, and health specifically for men, women, and children. Products also provide antioxidant benefits and support for bones and joints. Marketed under their prominent brands—Herbs of Gold, VitaHealth, and VitaScience—these offerings are sold through pharmacies and health food channels. Established in 1947, Vita Life Sciences Limited is headquartered in Kirrawee, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:06 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$2.54+A$0.04 (+1.6%)
Mayne Pharma Group Limited’s quoted price sits in the lower half of its reported 52-week range, 57.95% below the high.
A$0.36A$0.00 (0.0%)
Biome Australia Limited’s quoted price sits in the upper half of its reported 52-week range, 26.53% below the high.
A$0.37-A$0.01 (-1.35%)
Medical Developments International Limited’s quoted price sits in the lower half of its reported 52-week range, 49.31% below the high.
A$0.02-A$0.00 (-5.88%)
Peak Processing Limited’s quoted price sits in the lower half of its reported 52-week range, 33.33% below the high.
A$0.14A$0.00 (0.0%)
Star Combo Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 49.09% below the high.
A$0.31-A$0.01 (-1.61%)
EZZ Life Science Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 88.62% below the high.
A$0.03-A$0.00 (-10.81%)
Holista Colltech Limited’s quoted price sits in the lower half of its reported 52-week range, 63.33% below the high.
A$0.02-A$0.00 (-4.76%)
Epsilon Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
